TG Therapeutics Inc

TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its flagship product, BRIUMVI (ublituximab-xiiy), is a glycoengineered anti-CD20 monoclonal antibody approved in the U.S. for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BRIUMVI is also approved in several countries outside the U.S. for RMS with active disease. The company's development pipeline includes a subcutaneous formulation of BRIUMVI currently in Phase 3 trials, a Phase 3 program (ENHANCE) evaluating a simplified single-infusion initiation regimen, clinical trials expanding BRIUMVI into myasthenia gravis and treatment-resistant schizophrenia, and an azer-cel cell therapy platform being evaluated in progressive MS. Ex-U.S. commercialization is handled through a licensing partnership with Neuraxpharm. Updated Aug 3, 2026